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METHODS AND MATERIALS: All patients with histopathologically proven Stages IBeIVA
cervical carcinoma, treated at our institution with PDR intracavitary BT between April 1996 and
November 2007, were included in this retrospective analysis. All patients underwent primary pelvic
radiotherapy (45 Gy) with concomitant chemotherapy from 1999 and PDR intracavitary BT (16 Gy
to the clinical target volume), followed by hysterectomy in 124 patients.
RESULTS: Two hundred twenty-six patients received radiochemotherapy and BT. With a median
followup of 81.7 months, the 5-year overall survival, disease-free survival, and local control (LC)
were 67%, 65%, and 80%, respectively; seventy-seven relapses were observed including 38 local
recurrences. Multivariate analysis showed earlier FIGO (International Federation of Gynecology
and Obstetrics) stage and absence of nodal involvement to be associated with better overall and
disease-free survivals. Use of three-dimensional image-guided BT planning and absence of nodal
involvement were associated with better LC in the multivariate analysis. Late Grade $3 toxicity
was experienced by 22 patients (9.7%), consisting of gastrointestinal toxicity for 6 patients, urinary
tract for 10 patients, lymphatics for 3 patients, and vaginal toxicity for 3 patients.
CONCLUSIONS: This study demonstrates excellent LC rates with few late side effects with PDR
BT for cervix carcinoma, similar to those reported in the literature with historical standard
low-dose-rate BT.  2013 American Brachytherapy Society. Published by Elsevier Inc. All rights
reserved.Keywords: Pulsed-dose-rate brachytherapy; Cervical cancer; Image guided; Toxicity (side effects)Introduction
Brachytherapy (BT) is an integral part of the treatment
of cervical carcinomas, offering rapid dose falloff and very
high conformational dose distribution in comparison with
high-tech external beam irradiation. It offers a good thera-
peutic index with a high degree of local control (LC) andary 2013; received in revised form 14 May 2013;
3.
author. Department of Radiation Oncology, Institut
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33-5-56-33-33-76.
.quincy@bordeaux.unicancer.fr (L. Thomas).
nt matter  2013 American Brachytherapy Society. Publis
.1016/j.brachy.2013.05.003low toxicity (1e3). Continuous low-dose-rate (LDR) BT
has been routinely used for the treatment of cervix carci-
noma (1, 4), but high-dose-rate (HDR) BT was proposed
as an alternative because of advantages of using a single-
stepping source. Published oncologic results available for
HDR are similar to LDR. At the beginning of the 1990s,
pulsed-dose-rate (PDR) BT was developed combining
isodose distribution optimization of HDR BT and radiobio-
logic advantages of LDR BT. Brenner and Hall (5) and
Fowler and Van Limbergen (6) defined the conditions for
equivalence of continuous to pulsed LDR BT. Since these
publications, despite a lack of reported clinical results,
PDR BT has been increasingly used in practice in France,
replacing LDR.hed by Elsevier Inc. All rights reserved.
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10 years involving more than 200 patients with over 5 years
of followup for most patients. The aim of this clinical retro-
spective study was to present the results of this decade of
experience at our institution for patients with cervical cancer.Methods and materials
Patient and tumor characteristics
From April 1996 to November 2007, 226 patients with
invasive carcinoma of the cervixwere treated at our institution
with PDR intracavitary BT with curative intent. All patients
treated at our institution and for whom medical records were
available were selected for inclusion in this retrospective
study. Initial locoregional staging included a clinical evalua-
tion performed by a gynecologic surgeon and radiation oncol-
ogist (according to the 1995 FIGO (International Federation
of Gynecology and Obstetrics) classification (7)). Abdomino-
pelvic MRI was obtained for 168 patients (74.3%) and CT
imaging for 160 patients (70.8%). FDG-PET (fluorine-18-
fluorodeoxyglucose positron emission tomography) scan
was not systematically performed, and no decision has been
taken based only on its results; 148 patients (65.4%), mostly
Stages I and II, with a good health status and without suspi-
cious lomboaortic nodes atCTorMRIwere selected to receive
pelvic lymphadenectomy by coelioscopy first. Only 1 patient
had a para-aortic lymphadenectomy. Nodal involvement was
determined if histologically proven (65 patients) or suspected
on CT (24 patients). All patients with positive lymph nodes,
including IB1 stage, received first external beam radiation
therapy and are included in the study. Stage IB1 patients
treatedwith preoperative intracavitary PDRBT followedwith
colpohysterectomy were excluded from the analysis (19
patients). Institutional review board approval was obtained
for this study, and it was conducted in compliance with the
Helsinki Declaration.
Treatment characteristics
All patients received 45 Gy pelvic external beam radio-
therapy (EBRT) before PDR BT with a standard four-field
technique (190 patients) or a two anterior/posterior
opposing fields technique (36 patients) using high mega-
voltage photons from a linear accelerator (photons  18
and 25 MeV). EBRT included the para-aortic area when
the CT showed enlarged common iliac or para-aortic nodes.
When the nodal involvement was histologically proved or
suspected on CT, a complementary boost irradiation was
delivered after BT to reach a minimum of 60 Gy to the par-
ametria and/or involved pelvic nodes and 55 Gy to the para-
aortic nodes, taking into account the dose contribution of
BT. From 1999, based on the results of randomized trials
(8e12), chemotherapy was given during EBRT for all
stages $IB2, with intravenous cisplatin 40 mg/m2 once
a week for 5 weeks in 150 of 226 patients (66.4%).Chemotherapy courses were not delivered during the hospi-
talization for the BT procedure.PDR-BT procedure and treatment planning
After EBRT, the PDR BT boost was delivered during
a single hospitalization, using the PDR Selectron (Elekta,
Stockholm, Sweden). At the beginning of the BT procedure,
a careful clinical examination was carried out under general
anesthesia to assess clinical response to EBRT. A Fletcher
applicator was used, and no patient underwent interstitial
BT. Pulses were delivered hourly during night and day.
Before 1999, the BT treatment planning dosimetrywas based
on orthogonal radiographs, in accordance with International
Commission on Radiation Units (ICRU) 38 (13). The
prescribed dose was 16 Gy after radiochemotherapy. The
dose was reported according to the ICRU38 guidelines with
the 60 Gy isodose, total reference air kerma (TRAK), and
dose to critical organs (bladder and rectal reference points).
The dose distribution was calculated on orthogonal films
for 68 patients. Three-dimensional (3D) computerized-
assisted treatment based on CT (CT-based 3D PDR BT)
was adopted for treatment of cervical cancer since 1999
andwas carried out for 158 patients. CTat BTwas performed
with CTeMRI compatible Fletcher applicator in place and
with intravenous contrast except in cases of renal insuffi-
ciency or allergy. Clinical target volume (CTV) and organs
at risk (OARs) (rectum, sigmoid, bladder, and small bowel)
were delineated. CTV corresponded to the high-risk (HR)
CTV of the Brachytherapy Group of the European Society
for Therapeutic Radiology and Oncology (GEC ESTRO)
guidelines (14) and included the whole cervix and any
palpable or macroscopic residual disease. The BT dose was
prescribed on the target (HRCTVofGECESTRO). The dose
was calculated on minimal peripheral dose of the target, and
the dose rate prescribed was around 65 cGy/h that we have
used previously. Care was taken to obtain a similar TRAK
to that used previously with LDR BT. Concerning the
OAR, no consensus and guidelines were established in
1999; at the date, we began CT-based 3D PDR BT. Dose in
a low volume had been suggested to be well correlated with
dose at OAR, and a value of 3 cm3 was chosen. The dosee
volume constraints were doseevolume histograms (DVHs)
3 cm3 bladder #65 Gy (dose cumulated external irradiation
EBRT þ BT not calculated in EQD2 [equivalent dose in
2-Gray fractions]) and DVH 3 cm3 rectum #70 Gy. These
doses were extrapolated out of our experiencewith LDRwith
doses calculated to the ICRU points (bladder and rectum
reference points). The doseevolume constraints evolved
with current practices and after 2005; the doses were calcu-
lated according to GEC ESTRO recommendations on dose
reporting (24 patients). Until 2005, dose optimization was
performed using only dwell positions, modifications only
in the number of dwell positions in the uterine probe and
number and position of the dwell positions in the ovoids.
After 2005, graphical optimization was used (24 patients).
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According to the institutional gynecologic protocols,
a surgical procedure was decided for FIGO IB2eII tumors
with clinical assessment and MRI evaluation at the dose of
45 Gy, if the response to chemoradiation was less than
50%, for adenocarcinomas, in cases with initial extension
to the endometrium, or in cases in which BT treatment
was considered as nonoptimal. This surgical procedure con-
sisted in a radical colpohysterectomy or an extrafacial
hysterectomy. A pelvic lymph node dissection was per-
formed at the time of hysterectomy if not previously carried
out during the staging procedure: This had affected 16 of
the 124 patients who underwent surgery after BT. In 14
cases, patients were referred to our center for BT after ra-
diochemotherapy and did not receive an initial nodal
staging procedure. In two cases, patients had a nonresect-
able node during the staging procedure which could be
removed during the time of hysterectomy. Of the 16 final
lymphadenectomies, 6 were positive and patients received
a complementary boost of external irradiation on the
involved removed nodes.Table 1
Patient and tumor characteristics (n 5 226)
Characteristics n (%)
Age, yr (range) 52 (26e82)
Tumor size, mm
Median (range) 40 (15e85)
Histologic type













Positive 89 (39.4)Followup and statistical analysis
Patients were followed every 4 months for the first year
after treatment and then every 6 months until 5 years.
Thereafter, followup was done annually. Primary end
points were overall survival (OS) and disease-free survival
(DFS), and LC calculated from the date of diagnosis by the
KaplaneMeier method (15). Events taken into account for
OS were death of any cause, and for DFS relapses across,
all sites were taken into account. LC was assessed at clin-
ical examination and defined as absence of local recurrence
(centropelvic, lateropelvic, or vaginal). Locoregional recur-
rences included local and pelvic nodes recurrences. Lom-
boaortic metastatic nodes were considered to be
metastatic relapse. Median followup was calculated with
the reverse KaplaneMeier method.
Univariate analysis, taking into account age (!40 years),
FIGO stages (I and II vs. III and IV), nodal involvement
(pathologically staged and radiologically involved nodes),
histologic type, surgery, concomitant chemotherapy, and
response to chemoradiation as predictive factors for OS
and DFS, was performed using a log-rank test. For LC,
3D planning BT and BT dose prescription (D100 HR CTV
[EQD2 (10)]O15.8 Gy) were also analyzed. All variables
significant at p! 0.05 were then included in a multivariate
analysis with a Cox proportional hazards model using the
stepwise ascending method of maximum likelihood after
verification of data proportionality.
The secondary end point was analysis of complications
which were graded retrospectively using the Common
Terminology Criteria of Adverse Events (CTCAE v3.0).
Because of the difficulties in estimating low-grade toxic-
ities in retrospective studies, we focused on Grades 3 and4 toxicity, although grades for all side effects were identi-
fied. ‘‘Delayed or late’’ toxicities were defined as all toxic-
ities occurring after 6 months. Toxicities were compared
using Pearson’s c2 across treatment characteristics (surgical
procedure, adjunction of chemotherapy, dose of EBRT,
external irradiation technique, technical modalities of
EBRT, and laparoscopic lymphadenectomy). Across DVH
to bladder and rectum, toxicities were compared using
a ManneWhitney test.Results
Patient, tumor, and treatment characteristics
These characteristics are listed in Tables 1 and 2.
Median patient age was 52 years (range, 26e82 years).
The median pelvic dose was 45 Gy in 25 fractions, 5 days
a week. Fifty-one patients underwent a complementary
external irradiation boost (parametria and/or pelvic lymph
nodes) with a median dose of 9 Gy (range, 8e10 Gy).
The median dose for the PDR intracavitary boost was
16 Gy. From the beginning of EBRT to the PDR BT proce-
dure, the median time was 49 days (range, 30e91 days). A
surgical procedure was performed after PDR BT boost for
124 patients. Surgery was performed mainly in Stages I
and II patients (117 of 124) and 61.3% of Stages I and II
patients overall received complementary surgery (117 of
191). The details of the surgical indications are presented
in Table 2. Only 27 operated patients (21.7%) were in
complete pathologic remission.
Outcomes and survival
The median followup for all patients was 81.7 months
(6.8 years) (95% confidence interval [CI], 69.8e73.5). A
total of 77 failures were observed with 18.6 months (range,
4.9e71.8 months) median time of occurrence. Metastatic,
Table 2
Therapeutic characteristics





Dose, Gy (range) 45 (40e61)
Lomboaortic extended fields 39 17





TRAK, cGy/m2 (range) 1.2 (0.4e2.2)
60 Gy isodose volume, cm3 (range) 96.2 (17.1e337.5)
Height, mm (range) 76 (34e160)
Length, mm (range) 54 (30e75)
Width, mm (range) 46 (21e75)
Pulses (24/24) (range) 24 (12e50)
Dose rate, cGy/h (range) 65 (30e125)
Prescribed dose, Gy (range) 16 (8e28)
D100 HR CTV cm
3 [EQD2 (10)], Gy (range) 15.8 (6.4e28.3)
Point A, Gy (range) 17.1 (9.5e28)
Bladder ICRU, Gy (range) 11 (1.1e30)
Rectal ICRU, Gy (range) 18.7 (5.5e36)
DVH
Bladder 3 cm3 [EQD2 (3)], Gy (range) 17.8 (4.9e32.2)
Bladder 5 cm3 [EQD2 (3)], Gy (range) 15.4 (2.8e26.4)
Rectal 3 cm3 [EQD2 (3)], Gy (range) 7.7 (2.7e25)
Rectal 5 cm3 [EQD2 (3)], Gy (range) 6.3 (2.5e19)
Surgery
Yes 124 55
Response assessed!50% 77 62
Adenocarcinoma 33 27





EBRT5 external beam radiotherapy; TRAK5 total reference air ker-
ma; HR5 high risk; CTV5 clinical target volume; ICRU5 International
Commission on Radiation Units; DVH5 doseevolume histograms.
Fig. 1. Overall survival by FIGO stage for uterine cervix carcinoma
patients treated by pulsed-dose-rate brachytherapy (n 5 226).
Fig. 2. Disease-free survival by FIGO stage for uterine cervix carcinoma
patients treated by pulsed-dose-rate brachytherapy (n 5 226).
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(27.4%), 41 (18.1%), and 38 (16.8%) patients, respectively.
Among the 41 locoregional recurrences, 36 occurred within
the treated volume. The median delay to local relapse was
13 months (range, 5e71.8 months). Among the 62 patients
with metastatic failures, 36 were free of locoregional
failure during followup.
At 5 years, OS was 67% (95% CI, 0.60e0.73), DFS was
65% (95% CI, 0.58e0.71), and LC was 80% (95% CI,
0.74e0.85). OS, DFS, and LC are detailed according to
FIGO stages in Figs. 1e3.
Univariate analysis showed that more advanced FIGO
stage ( p 5 0.007, p 5 0.001, and p 5 0.006) and nodal
involvement ( p 5 0.001, p! 0.0001, and p! 0.001) were
predictive of poorer LC and shorter DFS and OS, respec-
tively. Age, histology, concurrent chemotherapy, consolida-
tion surgery, and response to chemoradiation were not
significant. Multivariate analysis confirmed the relationshipbetween shorter OS and DFS with more advanced FIGO
stage (hazard ratio, 1.8; 95% CI, 1.09e3.17), p 5 0.02
(hazard ratio, 2.71; 95% CI, 1.18e3.37), p 5 0.009 and
nodal involvement (hazard ratio, 2.0; 95% CI, 1.3e3.2),
p 5 0.001 (hazard ratio, 2.7; 95% CI, 1.7e4.3),
p ! 0.0001, respectively. In univariate analysis, FIGO
smaller stages (I and II), negative nodes, and use of 3D
BT planning were predictive of better LC p 5 0.012,
p5 0.001, and p5 0.003. TRAK$1.2 ( p5 0.37), comple-
mentary surgery ( p 5 0.09), and BT dose D100 HR CTV
O15.8 [EQD2 (10)] Gy ( p 5 0.71) were not significant.
For LC, multivariate analysis confirmed the significance
of nodal involvement ( p ! 0.0005; hazard ratio, 3.2;
95% CI, 1.6e6.3) and use of 3D imaging-guided BT plan-
ning (hazard ratio, 2.3; 95% CI, 1.22e4.53; p 5 0.01).
Early FIGO stages were not associated with better LC in
the multivariate model ( p 5 0.12). Comparisons with a
nonparametric Wilcoxon test were done to try to explain
this statistical benefice of 3D dosimetry in LC. There is
Fig. 3. Local control by FIGO stage for uterine cervix carcinoma patients
treated by pulsed-dose-rate brachytherapy (n 5 226).
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between patients treated used two-dimensional (97.8 cc;
range, 17.1e337.5) and 3D (95.8 cc; range, 43.2e326.2)
dosimetry plan ( p 5 0.7). Alike, doses to point A ( p 5
0.29) and TRAK ( p 5 0.45) were not statistically different
in these two groups.
Toxicity
Side effects are reported in Table 3. Of the 226 patients,
only 22 (9.7%) presented with delayed Grade$3 complica-
tions. Most patients developed only one Grade $3 toxicity
(n5 14). Seven patients developed two Grade$3 toxicities
and 1 patient developed three Grade $3 toxicities. Six
patients (2.6%) had gastrointestinal tract complicationsTable 3
Type and frequency of all Grade $3 toxicity
Side effects
Grade 3 Grade 4
n (%) n (%)
Gastrointestinal tract
Proctitis 2 (0.8) d
Fistula d 1 (0.4)
Colitis 1 (0.4) d
Stenosis 2 (0.8) d
Small bowel mucositis 1 (0.4) d
Overall 6 (2.6) 1 (0.4)
Genitourinary
Cystisis 1 (0.4) d
Urinary frequency d 1 (0.4)
Fistula d 3 (1.3)
Uretheral stenosis 7 (3.0) d
Overall 8 (3.4) 4 (1.7)
Female reproductive tract
Stenosis 3 (1.3) d
Lymphatics
Lymphedema 1 (0.4) d
Lymphocele 2 (0.8) d
Overall 3 (3.4) dand 10 patients (4.4%) had severe urinary tract toxicity
(Grade $3). Three patients (1.3%) experienced complete
obliteration of the whole vagina (Grade 3). Finally, 123
patients presented Grades 1 and 2 late vaginal side effects
(dryness, atrophy of the vaginal epithelium, partial syne-
chiae, or stenosis of the upper vagina). No statistically
significant increase in delayed Grade $3 toxicities was
observed for any treatment characteristics (EBRT dose!
45 vs. $45 Gy, two-field vs. four-field technique, surgery
or not, pelvic lymphadenectomy, and concurrent chemo-
therapy). Dose delivered to 3 cm3 ( p 5 0.01) or 5 cm3
( p 5 0.03) bladder was significantly higher in the group
of patients presenting Grade $3 urinary complications.Discussion
With 226 patients and a median followup of over
6.8 years, the present study represents one of the largest
series published in PDR BT. With 5-year LC of 85.3%
for Stages I and II, 71.4% for Stages III and IV, and
9.7% for Grade $3 late toxicity, our results compare favor-
ably with the published reports. Swift et al. (16) reported
clinical results of 65 patients with pelvic malignancies
(42 patients with primary cervical carcinoma) treated with
PDR BT with dose per pulse of 40e80 cGy/h. With
a median followup of 15.1 months, the incidence of Grade
$3 acute complications was 6.5%, which was not higher
than that with standard continuous LDR. They attributed
their low rate of complications to the isodose optimization
capabilities of PDR BT. Rogers et al. (17) reported
outcomes for a retrospective cohort of 46 patients with
cervical carcinoma treated with PDR BT. With a median
followup of 25 months, the overall 4-year DFS rate was
66% for the entire group, 100% for Stage IB, 69% for
Stage II, and 68% for Stages III and IV. The 4-year
actuarial complication-free survival rate for Grade $3
complications was 93%. More recently, Rath et al. (18)
reported the results of a retrospective study of 48 pa-
tients treated with PDR intracavitary BT for cervical carci-
noma. With a median followup of only 15 months,
cumulative recurrence-free survival for all patients, Stages
I and II, and Stages III and IV was 80%, 82%, and 78%,
respectively.
The PDR afterloading system has advantages; when
compared with previous LDR afterloading systems such
as source preparation and inventory are not needed, there
is only one source to replace every 3 months, and dosimetry
optimization and both intracavitary and interstitial brachy-
therapies are feasible. Indeed, for a given source strength,
the dose rate may be adjusted by modifying dwell times
and/or pulse intervals to optimize dose distribution. HDR
BT has the same advantages, using a single-stepping
source. Nevertheless, according to radiobiologic consider-
ations, the therapeutic ratio will be greater for LDR. Several
studies compare LDR BT as standard treatment vs. HDR
547A. Petit et al. / Brachytherapy 12 (2013) 542e549BT, with some contradictive results. A recent meta-analysis
pooled the results of randomized studies and concludes no
significant differences for survival and LC (19).
In interpreting these results, it is necessary to keep in
mind the range of radiation and BT technologies used in
these studies. PDR seems to be a good compromise
between LDR and HDR with radiobiologic advantages of
LDR and technical advantages of HDR. Only one prospec-
tive study has compared continuous LDR BT and PDR BT
for cervical carcinoma: 166 patients were analyzed
prospectively, 57 in the PDR BT arm. The dose rate was
similar in both groups (66 cGy/h in LDR and 70 cGy/h
in PDR arm). No differences were found for severe late
toxicity. The actuarial 3-year OS rate was 75% for both
groups, with no significant differences in 3-year DFS for
the PDR BT group (70% vs. 57%, p 5 0.19) (20).
Only one randomized prospective study suggests the
impact of LDR variations (21), with 204 patients with Stage
I and limited Stage II cervical cancer randomized to receive
one of two preoperative BT LDRs (0.4 and 0.8 Gy/h). The
investigators reported a greater late complications rate with
higher dose rate (38 cGy/h vs. 73 cGy/h), with no impact
on survival. Our results do not support this finding as we
find a low complication rate with a median dose rate of
65 cGy/h: 2.6% of gastrointestinal tract complications,
4.4% urinary tract severe toxicity, and 1.3% complete oblit-
eration of the vagina. These toxicity rates were in accor-
dance with those established with LDR. In the review by
Barillot et al. (22), 4% of late severe urinary toxicity and
2e4% of gastrointestinal tractus (35% for locally advanced
cancer) were established. We acknowledge the limitations
of this study owing to its retrospective assessment of
toxicity; however, with 50.6% Grades 1 and 2 late vaginal
effects, our rate is less than that reported by Potter et al.
(23) in a large series of HDR BT (78%).
In the multivariate analyses on outcomes, classical
clinical factors such as negative nodal involvement are
correlated with the 5-year LC but also the use of 3D-based
planning BT. Interest in BT 3D imaging planning has
increased and represents currently one of the most impor-
tant developments in gynecologic BT. Recently, guidelines
have been published by the GEC ESTRO (14, 24).
However, up until now, limited clinical evidence has been
published demonstrating the impact of 3D BT. Chargari
et al. (25) have been the first to report their experience with
MRI-based intracavitary PDR BT so far, for 45 patients
with locally advanced cervical carcinoma. The 2-year OS
was 78% without any Grade 4 toxicity and with only one
Grade 3 toxicity with a vesicovaginal fistula. The results
of the Vienna Group which studied MRI-based 3D HDR
BT (26) showed that improved treatment outcomes with
optimized 3D planning were achievable for patients with
larger target sizes ofO5 cm.
Recently, in a retrospective analysis, Kang et al. (27)
showed that the use of CT-based 3D BT resulted in a signif-
icant decrease of severe late rectal bleeding and in animprovement of LC for patients with tumor size O4 cm.
In a retrospective series including 84 patients with primary
locally advanced cervical carcinoma, Haie-Meder et al.
(28) suggest that applying individual treatment planning
with 3D MRI-guided LDR BT is feasible and efficient in
routine clinical practice and should become the standard
modality of gynecologic BT.
In 2006, A French prospective multicentric study STIC
PDR (Programme de Soutien aux Techniques Innovantes
Cou^teuses PulsedDoseRate) was initiated for patients treated
for cervix carcinoma comparing a PDR BT method based on
orthogonal x-rays (two-dimensional group) or based on 3D
imaging (3D group). Their results in the 3D arm at 2 years
(LC, locoregional control [LRC], and DFS) are relatively
similar to ours at 5 years for the two groups of patients with
surgery or not (29). For the group with surgery, 2-year LC
was 93% vs. 5-year LC was 86.3%, 2-year LRC was 88.6%
vs. 5-year LRC was 84%, and 2-year DFS was 77.1% vs.
5-year DFS was 68.3% in our series. For the group without
surgery, 2-year LC was 78.5% vs. 5-year LC was 79.4%,
2-year LRC was 69.6% vs. 5-year LRC was 75%, and
2-year DFSwas 60.3% vs. 5-year DFS was 60% in our series.
Preliminary dosimetric data are published for the first 637
patients: in the 3D arm, concerning the 267 patients treated
after EBRT with or without complementary surgery, D100
HR CTV is 10.8 and 16.6 Gy; D90 HR CTV is 17.9 and
26.8 Gy (30), respectively. Our retrospective study allows
us to compare only the D100 HR CTV [cm
3 [EQD2 (10)]. In
the group with surgery, our D100 HR CTV was 15.8 Gy cm
3
[EQD2 (10)] vs. 10.8 Gy cm
3 [EQD2 (10)] (STIC PDR). In
the group without surgery, our D100 HR CTV was quite
similar (16.85 Gy) cm3 [EQD2 (10)] vs. 16.6 Gy cm
3
[EQD2 (10)] (STIC PDR) (30). In these two series, the D100
HR CTV cm3 [EQD2 (10)] was lower than GEC ESTRO
recommendations (14). Dimopoulos et al. (26) obtained an
increase in LC rates of 95% if theD90 biologically equivalent
dose HR CTV was 87 Gy cm3 [EQD2 (10)] for patients
without surgery. Treatment policy in our series was individu-
ally tailored according to disease characteristics and response
to chemoradiation.Despite the lowdose level delivered, the 5-
year LC ratewas comparablewith traditional LDRBT studies
(79.4% for patients without surgery) even if recent 3D series
relate higher LC with generally more advanced tumors. As
example, P€otter et al. (31) related 3-year LC rate of 95% for
more advanced with 7.7% Grades 3e4 late complications.
Haie-Meder et al. (28, 31) reported a 2-year LC rate of
89.2% with low Grade 3 delayed toxicity (4.7%). Tan et al.
(32) in a series of 28 patients treated between 2005 and
2007 with CT-based guided HDR BT relate 3-year LC of
96%, with an overall actuarial risk of serious late morbidity
of 14%. Nevertheless, it raises the question of whether the
dose should be escalated to get better LC with a tolerable
complications rate. On the other hand, for nonresponders,
patients presenting with extensive disease, dose escalation
with image-based optimizationBTand use of additional inter-
stitial BT could be the best treatment (33).
548 A. Petit et al. / Brachytherapy 12 (2013) 542e549Conclusions and future implications
Considering the advantages of PDR BT, the present data
support PDR BT for the treatment of cervical cancer with
similar results to LDR BT in LC rates and few late side
effects. Our results indicate that this technique may be used
to replace standard LDR BT. The clinical impact of 3D-
based planning BT is demonstrated in this study, with
statistically significant better LC and should become the
standard for current gynecologic BT. The American Bra-
chytherapy Society published in 2012 guidelines concern-
ing LDR and PDR BT and recommended adoption of
GEC ESTRO recommendations and image-based treatment
planning (34). A dose escalation study in PDR BT with
optimized dosimetry based on MRI is currently underway
with the Tridicol French cooperative trial and the GEC
ESTRO multidimensional European observational study
of MRI-guided BT, ‘‘EMBRACE,’’ should also bring
further supporting data for this method.Acknowledgments
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